Form 8-K - Current report:
SEC Accession No. 0001193125-25-169818
Filing Date
2025-07-31
Accepted
2025-07-31 06:05:55
Documents
15
Period of Report
2025-07-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d35960d8k.htm   iXBRL 8-K 30885
2 EX-1.1 d35960dex11.htm EX-1.1 238143
3 EX-5.1 d35960dex51.htm EX-5.1 8254
7 GRAPHIC g35960g0730113425906.jpg GRAPHIC 2668
  Complete submission text file 0001193125-25-169818.txt   463883

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA lrmr-20250729.xsd EX-101.SCH 2856
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE lrmr-20250729_lab.xml EX-101.LAB 17994
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lrmr-20250729_pre.xml EX-101.PRE 11265
17 EXTRACTED XBRL INSTANCE DOCUMENT d35960d8k_htm.xml XML 3646
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 251169144
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)